Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study

Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study

BackgroundNeoadjuvant therapy is preferentially recommended for resectable locally advanced esophageal malignancies, with patients who achieve pathological complete response (PCR) anticipated to have longer survival rates. The aim of this study was to compare 3-year follow-up data for patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Hai Zhang, Haiquan He, Qingyi Feng, Bomeng Wu, Ying Chen, Zhenyang Zhang, Linrong Zhou, Cui Li, Wanli Lin, Jiangbo Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
esophageal squamous cell carcinoma
immunotherapy
neoadjuvant chemoradiotherapy
pathological complete response
recurrence-free survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1463936/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items